Metformin exercise interaction on glycemic control in patients with prediabetes and recent onset diabetes

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202401506460143

Enrollment

Registered

2024-01-09

Start date

2023-05-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine

Interventions

Placebo exercise group

Exercise metformin group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ?Increased waist circumference (=102 cm in men; =88 cm in women) ?Elevated triglycerides (=150 mg/dl), or on medication for treating the condition ?Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication for treating the condition ?High blood pressure (=130 mmHg systolic or =85mmHg diastolic), or on medication for treating the condition ?Elevated fasting glucose (=100 mg/dl), or on medication for treating the condition

Exclusion criteria

Exclusion criteria: Any condition that counter-indicate exercise Patients under glucose lowering agents

Design outcomes

Primary

Measure	Time frame
Disposition index - Beta-cell function;Mean 120min OGTT derived glucose ;Glycated Albumin	—

Secondary

Measure	Time frame
Insulin sensitivity;Mean 120min OGTT-derived insulin;Mean 120min OGTT-derived C-peptide;Insulin secretion rate;VO2 peak;Maximal fat oxidation ;Triglycerides;LDL-cholesterol;Total cholesterol;HDL cholesterol;Weight ;Body composition	—

Countries

Tunisia

Contacts

Public ContactJabeur Methnani

Researcher

jabeur.methnani@gmail.fr+21693201456

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026